Emily Bergsland, MD
Medical Oncology · San Francisco, CANPI 1295792729
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $482 of the $667 with a category attached, or 72.2%. 6 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 44.8% of the total. Reporting peaked in 2023 at $299 and has fallen 68.0% since, to $96 in 2025. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 6 payments — averaging $111.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$299
- Boehringer Ingelheim$183
- Sanofi$80
- Exelixis Inc.$65
- E.r. Squibb & Sons, L.L.C.$25
- Taiho Oncology, Inc.$16
Across 53 payments — averaging $64,902 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.7M
- E.r. Squibb & Sons, L.L.C.$714K
- Boehringer Ingelheim$44K
- Novartis$13K
- Boehringer Ingelheim International GmbH$785
- Boehringer Ingelheim Pharma GmbH & Co.kg$544
What the payments were for
- Speaking & faculty fees$48272%
- Travel & lodging$16124%
- Food & beverage$254%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 1 | $299 |
| Boehringer Ingelheim | 1 | $183 |
| Sanofi | 1 | $80 |
| Exelixis Inc. | 1 | $65 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Taiho Oncology, Inc. | 1 | $16 |
How this compares
$667 in reported general payments places this provider in the 25th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in San Francisco
- Stephen SherwinSan Francisco$6.9M
- John ParkSan Francisco$558K
- Kevin KimSan Francisco$176K
- Aman ChauhanSan Francisco$99K
- Ana Velazquez MananaSan Francisco$90K
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.